Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
890.9 USD | +0.87% | -1.07% | +1.39% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.39% | 95.28B | |
-2.87% | 103B | |
+1.46% | 22.15B | |
-16.15% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.36% | 16.05B | |
+4.82% | 13.68B | |
+33.11% | 12.17B | |
-24.98% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : FDA Accepts Regeneron's 'Regen-Cov" For Priority Review for Treatment, Prophylaxis of COVID-19